Press releases

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Copenhagen, Denmark, 12 September 2024 – Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) announced on 4 September 2024 that the Board of Directors had resolved on a rights issue of units with preferential rights for the Company's shareholders (the “Rights Issue”). The Danish Financial Supervisory Authority has today, on 12 September 2024, approved and registered the prospectus that Curasight has prepared in connection with the rights issue. The prospectus is available on Curasight's website (www.curasight.com) and Sedermera Corporate Finance AB's website (www.sedermera.se).

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Copenhagen, Denmark, 4 September 2024 – Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) today announces that the Board of Directors has resolved on a directed issue of units (warrants of series TO2 and series TO3) (the “Directed Issue”) to Fenja Capital II A/S (“Fenja”) and a preferential rights issue of units (warrants of series TO2 and series TO3) (the “Rights Issue”) to the shareholders in the Company, in accordance with the Company’s announcement on 14 June 2024. The proceeds from the warrants issued through the Directed Issue and the Rights Issue are to be used to fund the advancement of Curasight's pipeline within the field of radiopharmaceuticals, enabling the parallel development of the Company's diagnostic uTRACE® platform and radioligand therapy uTREAT® platform, as well as support activities connected to the ongoing collaboration with Curium Inc. The transaction ensures strategic flexibility, with the full financing extending the cash runway into the second half of 2025. The subscription period in the Rights Issue commences on 16 September 2024 and ends on 30 September 2024. A prospectus will be published when approved by the Danish Financial Supervisory Authority, prior to the subscription period.

Business Highlights during the second quarter 2024

· Strengthened financial base with funding of DKK 27.8 million and potential of up to DKK 120 million in total.
· Clinical trial application accepted by the European Medicines Agency (EMA) for the investigation of uTRACE[®] in a phase 2 trial in prostate cancer.
· Second milestone payment received under the agreement with Curium Inc. using uTRACE[®] for the improved diagnosis in prostate cancer. USD 0.5 million was triggered following enrollment of the first patient in the phase 2 trial in prostate cancer.
· Plans proceeding to accelerate therapeutic strategy to secure development in parallel to ongoing uTRACE[®] activities.

Copenhagen, Denmark, 22 August 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Interim report Q2 2024. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Copenhagen, Denmark, 30 July 2024 - Curasight A / S ("Curasight" or the “Company"- TICKER: CURAS) announces today that it has re-issued a total of 59,132 warrants as part of the Company’s existing long-term incentive program covering the Company’s Board of Directors, Executive Management and other key employees.

Copenhagen, Denmark, 2 July 2024 – today Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) held an Extraordinary General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark

Copenhagen, Denmark, 01 July 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) today announces that the directed issues decided by the Board of Directors and announced on the 14[th] of June 2024 are now registered at the Danish Business Authority. The directed issues increase the Company's number of shares from 19,893,891 to a total of 20,682,427 shares. The Company's share capital will increase from DKK 994,694.55 to a total of DKK 1,034,121.35. The new shares are expected to be in the subscribers’ accounts around the 4 of July 2024.

Copenhagen, Denmark, 22 June 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the new capitalization and funding of the company at HC Andersen Capital 25 June 2024.

The Board of Directors is pleased to invite shareholders of Curasight A/S (“Curasight” or the “Company”) to an Extraordinary General Meeting on

Tuesday 2 July 2024 at 10:00 AM (CET) at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Copenhagen, Denmark, 14 June 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) today announces that the Board of Directors has resolved to execute directed issues of shares of a total of approximately DKK 7.8 million. The Company also intends to execute a directed issue of units, consisting of warrants, to Fenja Capital II A/S (“Fenja”) as well as a preferential rights issue of units, consisting of warrants, to the existing shareholders. Curasight has also secured a loan facility of in total DKK 20 million from Fenja and from the loan facility the Company has decided to immediately draw a tranche of DKK 10 million. The proceeds from the total capitalization are to be used to fund the advancement of Curasight’s pipeline within the field of radiopharmaceuticals, enabling the parallel development of the company’s diagnostic uTRACE® platform and radioligand therapy uTREAT® platform, as well as support activities connected to the ongoing collaboration with Curium Inc. The transaction ensures potential new funding up to DKK 120 million and strategic flexibility, with the full financing extending the cash runway into the second quarter of 2025.

· Recruitment of first patient triggers second milestone payment of USD 500.000 to Curasight under the collaboration agreement for uTRACE[®] in prostate cancer with Curium Inc.
· Milestone is an important step in the development of the uTRACE PET imaging technology, part of Curasight’s theranostic platform leveraging the uPAR target for improved diagnosis (uTRACE[®]) and radioligand treatment (uTREAT[®]) of certain cancers
· Under the agreement signed with Curium Inc. in 2023, Curasight is eligible to receive up to mUSD 70 in development and commercial milestones plus double-digit royalties on sales upon commercialization

Copenhagen, June 12, 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) today announced the enrolment of the first patient in the Phase 2 trial using uTRACE[®] PET imaging technology for the improved diagnosis in prostate cancer. The news triggers the second USD 500.000 milestone under the agreement with Curium Inc., signed in May 2023. uTRACE[®] is part of Curasights Theranostic platform using the uPAR target for improved diagnosis and treatment (uTREAT[®]) of certain cancers.